Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer

S. Zhong, C. R. Fields, N. Su, Y. X. Pan, Keith D Robertson

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression profiling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently downregulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.

Original languageEnglish (US)
Pages (from-to)2621-2634
Number of pages14
JournalOncogene
Volume26
Issue number18
DOIs
StatePublished - Apr 19 2007
Externally publishedYes

Fingerprint

Gene Expression Profiling
DNA Methylation
Epigenomics
Non-Small Cell Lung Carcinoma
Histones
Cystatin M
Lung Neoplasms
Activating Transcription Factor 3
Down-Regulation
Growth
Biomarkers
Oxytocin Receptors
Genes
Lung
Regulator Genes
Acetylation
Tumor Cell Line
Neoplasms
Carcinogenesis
Genome

Keywords

  • 5-aza-2′-deoxycytidine
  • DNA methylation
  • Histone acetylation
  • Lung cancer
  • Microarray
  • Trichostatin A

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. / Zhong, S.; Fields, C. R.; Su, N.; Pan, Y. X.; Robertson, Keith D.

In: Oncogene, Vol. 26, No. 18, 19.04.2007, p. 2621-2634.

Research output: Contribution to journalArticle

@article{8264d7c1afc545cd9e7ca64f6b1bf76f,
title = "Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer",
abstract = "Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression profiling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently downregulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.",
keywords = "5-aza-2′-deoxycytidine, DNA methylation, Histone acetylation, Lung cancer, Microarray, Trichostatin A",
author = "S. Zhong and Fields, {C. R.} and N. Su and Pan, {Y. X.} and Robertson, {Keith D}",
year = "2007",
month = "4",
day = "19",
doi = "10.1038/sj.onc.1210041",
language = "English (US)",
volume = "26",
pages = "2621--2634",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "18",

}

TY - JOUR

T1 - Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer

AU - Zhong, S.

AU - Fields, C. R.

AU - Su, N.

AU - Pan, Y. X.

AU - Robertson, Keith D

PY - 2007/4/19

Y1 - 2007/4/19

N2 - Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression profiling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently downregulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.

AB - Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression profiling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally downregulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently downregulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.

KW - 5-aza-2′-deoxycytidine

KW - DNA methylation

KW - Histone acetylation

KW - Lung cancer

KW - Microarray

KW - Trichostatin A

UR - http://www.scopus.com/inward/record.url?scp=34247373911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247373911&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1210041

DO - 10.1038/sj.onc.1210041

M3 - Article

C2 - 17043644

AN - SCOPUS:34247373911

VL - 26

SP - 2621

EP - 2634

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 18

ER -